Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Every year if you buy this TAX LOSS SELLING, in December, you make great returns by mid year !!
Conference Call at 4:30 pm est today. with questions and answers. Anyone going to ask when estimated trial results will be available in 2019?
Earnings posting mid December, hope we get trial updates. I think we get a partner soon in 2019 imo.
BABA forms partnership with UXIN. UXIN could be huge.
Should be trading at $5 at least
Phase II data and Phase II PK data on January 18th and 2 more posters. Could we move above $25 ?
Time to open up to a Buyout at $40 or a partnership at $20
I think we all feel we wake up soon to a partnership above $10 and then a buyout over $30+ BP loses 10b every time they fail AD trials. AVXL is a bargain and we all know it.
BABA changing to Cloud. Buying PLAN ? Someone will if not BABA.
Remind me what is the best guess on brain cancer phase 3 final results and FDA approval?
PACB buyout for 1.2 Billion. AVXL would be $30. ANY day now imo.
This deal now values PLAN at $50-$100 or 6B to 12 Billion. They are stealing top cloud companies will new platform. Recent IPO.
PFE or BMY will scoop up AVXL. Best science has now been verified on multiple fronts and they all know now.
This deal easily values PLAN at $50-$100 or 6B to 12 Billion.
Did AVXL just stabilize Alzheimers for years at CTAD?
PFE and BMY desperately need a pipeline. BIIB, GILD, MRK, JNJ always looking but my guess is PFE or BMY.
NBEV a 5 bagger from here and IGXT a 10 bagger imo. TLRY sighs letter of intent with IGXT for oral sublingal CBD strips like the Listerine ones.
Australia's socialized medicine truly is aggressively looking to save billions with an Alzheimers treatment. In its path is billions more in savings for other CNS diseases. Worldwide, Anavex will be known !
Morning Gap Ups will occur more often. The chart is poised for a huge breakout and uncoiling. The Brilliance of this new science and drug for CNS diseases will bring this quickly to triple digits before all know about it imo.
Billion dollar drug. There are less than 20,000 cases of Rett diagnosed per year so lets take 10,000 x $100,000 cost = 1 Billion annually. Just a billion MC is $35. No current treatment for this ugly disease.
Money moving to PLAN
See PTI today? That move coming to AVXL imo.
PLAN is the innovator in Cloud and stealing major customers. Recent IPO.
Canada legalizes 10-17-18. Buying DTEA and NBEV.
AVXL,WVE and ALLO big movers this month imo.
Yanks I agree. Here is the Comparison. SQ projects FY18 adj eps .39-.41c and IIIV projects FY19 .79-.81c ! SQ Market Cap is 40 Billion trading at $100 and IIIV trading at 215 Million MC and growing very fast. Its like when I bought SQ early , I am buying IIIV.
NEWS: SQ crosses $100 and IIIV projects FY19 adj eps .79-.81c while SQ projects FY18 .39-41c. Adding IIIV .
So on October 8, NBEV showcases CBD beverages in Vegas. Will POTN?
IIIV could easily reach $45-$55 on projected FY19 adj eps of .79-.81.. SQ only has projected FY18 adj eps .39-.41. Both payment systems will be monsters imo.
Two comparisons: SQ announces FY18 adj eps .39-,41c but IIIV announces FY19 adj eps .79-.81. IIIV has much less shares and Market Cap too.
Two competitors: SQ announces FY18 adj eps .39-,41c but IIIV announces FY19 adj eps .79-.81. IIIV has much less shares and Market Cap too.
XON and LEVB announce CBD news, XON 68m float but LEVB only 6m float.
News: LEVB showcases CBD. Only 6 million in float. Kathy Ireland making it a powerhouse !
SQ and IIIV continue to be my favorite payment stocks with IIIV projecting FY19 adj eps .79-.81c and SQ projects FY18 adj eps .39-.41c
My money will double from these levels. Cant do that at the bank !
Update Market caps: SQ 37 Billion, PYPL 108 B, WP 30 B. IIIV only 600 million. At $40 = only 1 Billion. Buying IIIV. They project FY19 adj eps .79-.81 and SQ projects FY18 adj eps ,39-.41
No bad news has come because trials haven't even began ! So RELAX
This will jump as trials are finished with results. The lower I can buy the easier it is to double my money on good news.
I am hoping its soon since on last CC Missling said 3 trials to start by end of year.
Who is ready to wake up to some Amazing News?
SQ projects FY18 adj eps .39-.41 and IIIV projects FY19 adj eps .79-.81c. I am grabbing IIIV payment systems early like I did SQ.